What we do

What we do

Market Access Strategy

We support you in the development and the tailoring of the market access strategy according to therapeutic area, business potential, and company resources.

Market Access Portfolio/Product Assessment

We can map the current market access situation, risks and opportunities for new products when entering a new therapeutic area or region.

Reimbursement Submissions

We can support you in the process from the development of reimbursement dossiers to the actual filing process with support during the evaluation and negotiation process.

Health Economics

Cost-effectiveness, cost-utility, cost-benefit, budget impact, value tools. We build models and we adapt them to fit your needs.

Market Access Training

We can do training sessions providing an overview of the market access landscape and recent developments or tailored training sessions for specific therapeutic areas or health economic theory.

Data and Real-world evidence

Advanced analytics, machine learning, and deep learning – we know the science behind the buzz words – We believe in data-driven decision making and can support you in data analytics, statistical modelling, indirect treatment comparisons, register studies, survival analysis, if it’s data – we do it…

Who we are

We have long and broad experience of market access in the Nordics and beyond – in therapeutic areas spanning from highly specialized products and rare diseases to primary care products at both the national and regional payer levels.

NMA 2019

Kajsa Olsson


Kajsa Olsson has more than 18 years of experience from Market Access, pricing and reimbursement in the Swedish and Scandinavian markets. In her most recent role, she was heading the Swedish Market Access department at Novartis Oncology. In former roles, she has been responsible for establishing and leading market access departments in both Schering-Plough and Bayer as a member of Swedish or Scandinavian leadership teams.

Kajsa Olsson has extensive experience from pricing and reimbursement processes and reimbursement submissions for new products across several countries and disease areas. Additionally, she has also been responsible for leading teams supporting regional market access. Her therapeutic area experience includes oncology, hematology, women’s health, immunology, cardiology, allergy/asthma, ophthalmology and rare diseases providing market access over the entire lifecycle of the products from launch to mature products and loss of exclusivity.

+46(0)703-24 37 62

Peter Carlqvist


Peter has a background in drug discovery – with a strong academic foundation: Master’s in chemical engineering, Bachelor of Science in Statistics, and a PhD in Quantum Chemistry. Peter has 20 years of experience in the modelling and communication of complex systems. In the last 10 years Peter has focused exclusively on health economic modelling, outcome research and market access.

Peter has extensive experience in health technology assessment with the development and adaptation of more than 50 economic models both as a consultant and as an industry health economist. Further, Peter was Head of Market Access at Kyowa Kirin Nordics and Baltics bringing products in rare disease to market, giving him understanding beyond technical challenges.

+46(0)702-46 52 97